Abstrakt
Background: To report single-institution experience with minimally invasive mitral valve operations through the right minithoracotomy over a 5-year period. Methods: Patients who underwent minimally invasive mitral valve surgery (MIMVS) between January 2012 and December 2016 were included.
Clinical follow-up data were collected in a prospective database and analyzed retrospectively. Results: Data from 151 patients were assessed (mean age, 63.4 +- 9.7 years; 55% were females).
Overall 30-day mortality was 0.7% (n = 1). Mean operating time, cardiopulmo-nary bypass, and aortic cross-clamp times were 254.9 +- 48.7, 140.5 +- 36.1, and 94.8 +- 27.0 minutes, respectively.
Associated procedures were tricuspid valve annuloplasty (37.1%, n = 56) and closure of atrial septal defect (6.0%, n = 9). Cryoablation was performed in 43.7% of patients (n = 66).
One patient (0.7%) required conversion to median sternotomy and six patients (4.0%) underwent re-explorations due to bleeding. Median postoperative hospital stay was 12 days.
Overall survival at 5 years was 94.1% +- 2.0%. Freedom from reoperation was 94.6% +- 2.9% at 5 years.
Conclusions: MIMVS is a feasible, safe, and reproducible approach with low mortality and morbidity. Mitral valve surgery through a small thoracotomy is a good alternative to conventional surgical access.
